Volagidemab (development name REMD-477) is a monoclonal antibody that targets the glucagon receptor. It is developed by REMD Biotherapeutics for type 1 and type 2 diabetes.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.